International Journal for Autism Challenges & Solution
Vol 1 Issue 1 (2024)
Pages (39 - 50)

Available at www.emiratesscholar.com

Maternal Immune Activation and Autism Spectrum Disorder: Complex Interactions and Therapeutic Possibilities

Geir Bjørklund[1], Ramesa Shafi Bhat [2], Afaf El-Ansary[3]

[1]*Council for Nutritional and Environmental Medicine (CONEM), Mo i Rana, Norway*

[2]*Biochemistry Department; Science College of King Saud University, Riyadh, Saudi Arabia.*

[3]*Autism Center, Lotus Holistic Alternative Medical Center, Abu Dhabi, United Arab Emirates*

Abstract

This review examines the intricate association between maternal immune activation (MIA) and autism spectrum disorder (ASD), emphasizing the impact of maternal infections during pregnancy. Epidemiological studies link viral and bacterial infections to an elevated risk of ASD, revealing the complex interplay between environmental factors and neurodevelopmental outcomes. Immunological mechanisms, including cytokine dysregulation and neuroinflammation, involve key players such as interleukin-6 and tumor necrosis factor-alpha, influencing fetal brain development and ASD risk. Genetic and environmental interactions contribute to individual susceptibility, with specific variants influencing MIA's impact on ASD risk. Epigenetic modifications provide a molecular link between environmental exposures, including MIA, and enduring neurodevelopmental changes. Recognizing critical periods during fetal neurodevelopment susceptible to MIA is crucial. Long-term studies highlight enduring consequences on behavior and cognition into childhood and adolescence. Exploring potential therapeutic interventions, including immunomodulatory strategies during pregnancy, offers hope for mitigating MIA's impact on ASD outcomes. Despite progress, knowledge gaps persist, motivating future research guided by emerging technologies and interdisciplinary approaches to unravel the intricate MIA-ASD relationship.

Keywords: autism; maternal immune activation; neurodevelopment; cytokine dysregulation; genetic susceptibility; epigenetics.

Email Address: bjorklund@conem.org

1. Introduction

Autism spectrum disorder (ASD) represents a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors [1]. With a prevalence that has been steadily increasing over recent years, ASD has become a major public health concern, impacting individuals across the lifespan and placing a substantial burden on families and society as a whole. Understanding the etiology of ASD is essential for developing effective prevention and intervention strategies.

The etiology of ASD is recognized as multifactorial, involving a complex interplay of genetic and environmental factors [2,3]. While considerable strides have been made in identifying genetic contributions, environmental influences remain a critical area of investigation. Recognizing and understanding these risk factors not only provides insights into the fundamental mechanisms of ASD but also offers opportunities for early identification, intervention, and, ultimately, prevention [4].

One emerging area of research on the environmental factors contributing to ASD is maternal immune activation (MIA) [5,6]. Maternal immune responses during pregnancy, particularly those resulting in inflammation, have been proposed as potential contributors to atypical neurodevelopment and increased ASD risk in offspring [7,8]. This hypothesis stems from the recognition that the maternal immune system undergoes dynamic changes during gestation, and disruptions to this balance may impact the developing fetal brain.

This review aims to delve into the existing literature on MIA as a potential risk factor for ASD. Examining the relationship between maternal immune activation and neurodevelopmental outcomes in offspring seeks to provide a balanced and critical synthesis of the current state of knowledge.

2. Neurodevelopment and Autism Spectrum Disorder

The neurodevelopmental processes leading to ASD are intricately orchestrated, beginning in utero and extending into early postnatal life [9]. Neural progenitor cells are crucial in differentiation, migration, and establishing intricate neural circuits. This cellular diversity is fundamental for forming the complex neural circuits that underpin cognitive, emotional, and social functions. Disruptions in the precise orchestration of these events can contribute to neurodevelopmental disorders, such as ASD [10]. Identifying aberrations in the differentiation, migration, or circuit formation of neural progenitor cells is pivotal for understanding the etiology of these disorders. A comprehensive understanding of normal neurodevelopment is essential for unraveling the complexities of neurodevelopmental disorders and facilitating targeted interventions and therapeutic strategies [11].

Individuals with ASD exhibit discernible disruptions in various facets of neurodevelopment, as revealed by neuroimaging studies [12,13]. Structural deviations in critical brain regions responsible for social cognition, language processing, and sensory perception highlight the neuroanatomical underpinnings of ASD. Dysregulation in neurotransmitter systems, impacting synaptic plasticity and neural communication, contributes to the observed cognitive manifestations in individuals with ASD [14]. Myelination, crucial for efficient signal transmission, also plays a role in ASD, with disruptions in myelination patterns implicated in altered connectivity and diverse behavioral manifestations. The multifaceted disruptions in brain structure, neurotransmitter systems, and myelination collectively shape the neurobiological landscape of ASD, providing insights for targeted interventions and therapeutic strategies [15].

The immune system's influence on neurodevelopment is crucial, with immune cells and molecules orchestrating a balanced microenvironment for optimal brain maturation. Dysregulation of immune responses during critical neurodevelopmental periods can contribute to the emergence of neurodevelopmental disorders. MIA in ASD is a significant area of investigation, as maternal immune responses can modulate the fetal immune environment, influencing neurodevelopment trajectories. Understanding the delicate balance between neurodevelopment and ASD, particularly through MIA, provides nuanced insights into the onset and manifestation of ASD.

3. Maternal Immune Activation

MIA is an intricate and extensively researched phenomenon, exploring its profound implications on neurodevelopment in offspring [16]. Triggered by various stimuli such as viral or bacterial infections, exposure to environmental toxins, and maternal autoimmune conditions, MIA initiates a cascade of inflammatory responses, releasing pro-inflammatory cytokines, chemokines, and other immune signaling molecules [17-20]. These mediators, notably interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and IL-1β, play pivotal roles in immune regulation but, when overproduced during pregnancy due to MIA, may adversely impact fetal neurodevelopment [21-23]

The developing fetal brain, particularly vulnerable during critical periods of neurogenesis and synaptogenesis, faces potential disruptions in the intricate processes governing neural circuit formation. MIA has been associated with an elevated risk of neurodevelopmental disorders, including ASD and schizophrenia, although the precise mechanisms remain under investigation. Hypotheses suggest direct effects on neuronal progenitor cells, alteration of neurogenesis, and disturbance in the balance of excitatory and inhibitory neurotransmission.

Recent strides in molecular and cellular neuroscience, utilizing animal models, primarily rodents, to elucidate the neurobiological changes induced by MIA, have provided valuable insights. These studies contribute to identifying potential therapeutic targets to mitigate the adverse effects on neurodevelopment [24].

The maternal immune response during pregnancy balances tolerance to the semi-allogeneic fetus and defense against pathogens [25]. An anti-inflammatory state, marked by increased regulatory T cells (Tregs) and decreased pro-inflammatory responses, establishes immune tolerance crucial for successful pregnancy outcomes [26]. The placenta acts as a selective barrier, permitting nutrient passage while limiting immune cell transmission. Disruptions in this balance can lead to immune activation, which is implicated in the pathophysiology of MIA [27].

Understanding the genetic and environmental determinants of MIA susceptibility is paramount. Genetic factors influencing immune regulation and response, alongside environmental triggers like infections and stressors, contribute to heightened immune activation [28]. The timing of immune challenges during distinct gestational stages critically influences neurodevelopment, with immune challenges potentially disrupting fundamental processes at different stages [29].

Animal models, particularly rodents and non-human primates offer controlled environments in which to study the causal link between MIA and ASD-like outcomes [30]. Rodent models, inducing immune activation in pregnant individuals, replicate ASD-like phenotypes in offspring, including social deficits and cognitive impairments [31-32]. Non-human primates, closer to humans genetically, enhance translational relevance [33].

These models allow the manipulation of variables to simulate various aspects of MIA, aiding in exploring maternal immune responses' dynamics and their impact on neurodevelopment. They also serve as testing grounds for potential interventions, offering insights into therapeutic strategies to alleviate the consequences of MIA on neurodevelopment and mitigate the risk of ASD in offspring. As our understanding grows, these animal models remain indispensable in guiding the development of targeted interventions and therapeutic strategies. The interdisciplinary approach, bridging immunology, neuroscience, and developmental biology, is pivotal in unraveling the multifaceted factors influencing MIA and its profound impact on the developing fetal brain.

4. Epidemiological Insights into ASD Etiology

The etiology of ASD is intricate and multifaceted, with a burgeoning body of research spotlighting maternal infections during pregnancy as a potential contributing factor. Diverse infectious agents, spanning viruses and bacteria, have been scrutinized through retrospective and prospective study designs [34-36]. The MIA hypothesis is central to this exploration, positing that the maternal immune response to infections during pregnancy may influence ASD development in offspring [36-37] . Specific viruses like influenza, herpes simplex, cytomegalovirus, and various bacterial infections have been investigated, emphasizing the need for a comprehensive understanding of potential mechanisms [38-41].

Methodologically, studies encompass a spectrum from case-control to cohort designs, utilizing

population-based registries and targeted serological approaches. This diversity allows nuanced exploration of exposure timing, infection severity, and individual susceptibility. Despite mixed and sometimes conflicting results, evidence points toward an increased ASD risk associated with maternal infections during pregnancy. However, the specific mechanisms driving this association remain actively researched. Immune system dysregulation, neuroinflammation, and altered fetal brain development are proposed pathways contributing to the evolving comprehension of MIA in ASD etiology [42].

Longitudinal cohort studies play a pivotal role in unraveling the complex relationship between maternal immune responses and ASD occurrence. These studies track individuals over extended periods, revealing developmental trajectories in those exposed to varying degrees of maternal immune activation. Insights into potential causal links and time-dependent factors influencing ASD risk emerge through meticulous case-control analyses, examining specific antibodies, cytokine levels, or other immune markers in mothers of children with ASD [43].

Retrospective investigations and analysis of historical data add another dimension by exploring maternal immune history in individuals diagnosed with ASD [44]. Patterns linking specific immune activations during pregnancy and early childhood to later ASD development are sought. Such investigations contribute crucial information for establishing potential risk factors and refining hypotheses from other study designs.

Epidemiological studies, while instrumental, face challenges that demand careful consideration. Recall bias, stemming from reliance on participants' memory, poses a notable limitation, potentially skewing the association between maternal infections and ASD outcomes. The complexity of confounding variables, encompassing socioeconomic status, genetics, and environmental factors, requires meticulous adjustment to isolate the true impact of immune activation on ASD risk [45].

Scrutiny of the diverse methodologies employed in epidemiological studies is imperative. Cross-sectional, cohort and case-control designs bring unique strengths and weaknesses, necessitating a comprehensive understanding to draw meaningful conclusions. Variability in pathogen types, severity, and timing of exposure introduces nuances that must be meticulously considered. A rigorous assessment of individual study strengths and limitations, including sample size, control for confounding variables, and statistical methodologies, is essential for discerning the reliability of reported associations.

In critically examining existing epidemiological evidence, researchers must remain vigilant in addressing challenges. The field's advancement hinges on navigating the intricacies of maternal health, immune responses, and neurodevelopmental outcomes in offspring. Vigilance in refining methodologies, exploring specific pathways, and considering potential confounding factors will propel understanding of the complex interplay between maternal infections, immune activation, and ASD.

5. Immunological Mechanisms

Pregnancy entails intricate adaptations in the maternal immune system to foster a balance between tolerance to the semi-allogeneic fetus and defense against potential threats. Regulatory T cells and the placenta promote immune tolerance, while trophoblast cells modulate the maternal immune response [26]. Across trimesters, the immune system undergoes nuanced adaptations, shifting from an anti-inflammatory state in the first trimester to controlled inflammation in the second and third trimesters, ensuring protection without compromising fetal well-being [46-47].

MIA, triggered by infections, stress, or environmental factors, disrupts this equilibrium and is implicated in neurodevelopmental outcomes, particularly the risk of ASD [48]. Inflammatory molecules, such as cytokines, breach the placental barrier, impacting fetal brain development. Central to immune responses, cytokines orchestrate balances crucial for overall health. In MIA, heightened pro-inflammatory cytokine release, including IL-6, IL-1β, and TNF-α, influences fetal neurodevelopment and is associated with neurodevelopmental disorders [48-53].

Cytokine dysregulation, particularly IL-6 and TNF-α, has far-reaching consequences. These cytokines traverse the placental barrier, directly affecting neural progenitor cells and disrupting neurogenesis. Additionally, TNF-α contributes to alterations in neuroinflammation, impacting synaptic

processes and neuronal migration critical for neurodevelopment. Microglial activation, central to neuroinflammation, disrupts synaptic pruning, neuronal migration, and differentiation, leading to long-lasting effects on neural circuits observed in ASD [54-57].

Neuroinflammation activates microglia, initially protective but disruptive during MIA, releasing inflammatory mediators [58]. This disrupts synaptic pruning and interferes with neuronal migration and differentiation, contributing to altered connectivity between neurons, a hallmark of ASD. The chronic nature of neuroinflammation may link to long-term neuronal health, prompting exploration into its potential neurodegenerative aspects.

Maternal immune responses affect neural progenitor cells, hindering proliferation and influencing the differentiation process, potentially contributing to aberrations in neural circuitry. The compromised blood-brain barrier during MIA allows immune cell infiltration and the influx of inflammatory molecules, intensifying neuroinflammation.

6. Genetic and Environmental Interactions

Genetic factors significantly influence ASD susceptibility, with identified mutations, copy number variations, and rare de novo mutations contributing substantially. Despite these findings, a considerable portion of ASD risk remains unexplained, prompting further investigation into the intricate interplay between genetic and environmental factors. Notably, MIA, characterized by the mother's immune response during pregnancy, is a potential environmental influencer of ASD risk [37]. Children born to mothers experiencing MIA display an increased likelihood of ASD development [37]. Emerging evidence suggests that specific genetic variants may not only contribute to ASD susceptibility but also influence immune dysregulation, impacting responses to maternal infections or inflammatory signals. Ongoing research focuses on identifying genetic markers associated with increased susceptibility to ASD and immune dysregulation in MIA. Advancements in genomics and collaborative efforts pave the way for a more comprehensive understanding of MIA-induced ASD genetics. Recognizing individual genetic heterogeneity can inform personalized interventions and therapeutic strategies.

The evolving understanding of ASD emphasizes the interplay between genetic predispositions and environmental influences, epitomized in gene-environment interactions [59]. Genetic vulnerabilities related to neurodevelopmental processes, synaptic function, and immune system regulation significantly contribute to ASD susceptibility [60]. Within this complexity, MIA, triggering maternal immune system activation during pregnancy, has emerged as a notable environmental factor implicated in ASD [5]. The exploration of MIA illustrates how environmental exposures during fetal development influence neurodevelopment and contribute to lasting consequences. Understanding the interplay between MIA and genetic vulnerabilities reveals the potential for specific genes to modulate the impact of environmental exposures, contributing to the variability in ASD risk and manifestation. This underscores the importance of genetic and environmental factors in autism research.

The central theme in gene-environment interactions of ASD revolves around the modulatory role of genetic profiles in response to environmental exposures. Specific genetic variations may heighten vulnerability to the effects of MIA, emphasizing the heterogeneity of ASD [61]. This individualized response underscores the need for personalized approaches to diagnosis and intervention. Current research endeavors leverage genomics, epigenetics, and environmental science to unravel how specific genes interact with environmental factors, informing a more holistic and individualized approach to ASD study and management [62]. Decoding gene-environment interactions holds significant implications for precise diagnostic tools, tailored interventions, and therapeutic strategies.

Epigenetic modifications, characterized by changes in gene expression without altering DNA sequence, play a pivotal role in understanding how environmental factors, particularly MIA, impact neurodevelopment [63]. MIA consistently links to alterations in DNA methylation patterns and histone modifications, influencing gene expression during neurodevelopment. The complex interplay between genetic susceptibility, environmental factors, and epigenetic changes amplifies vulnerability to MIA, contributing to ASD risk. Examining effects on neural progenitor cells and blood-brain barrier integrity provides insight into how immune responses during pregnancy shape ASD pathophysiology. The complexities of epigenetic alterations in MIA are

central to understanding maternal immune activation's multifaceted influence on neurodevelopment, encompassing genetic susceptibility, gene-environment interactions, and neuroinflammation [64].

7. Timing and Duration of Maternal Immune Activation

Critical periods in fetal neurodevelopment represent pivotal windows during pregnancy, characterized by heightened susceptibility to external influences. Disturbances within these periods can result in enduring consequences for neurological outcomes. The intricate orchestration of processes, including neuronal proliferation, migration, differentiation, and synaptogenesis, unfolds precisely during these phases to establish complex neural circuitry. MIA during pregnancy is identified as a potential influential factor, with its effects varying based on the timing of exposure [65].

The developing fetal brain's vulnerability to external influences is non-uniform across gestation, fluctuating with ongoing neurodevelopmental processes. The relationship between MIA and critical periods aligns with the temporal dynamics of its impact on the fetal brain, particularly during key developmental stages. Associations with neurodevelopmental disorders, such as ASD, characterized by impaired social interaction, communication difficulties, and repetitive behaviors, have been a focal point in understanding prenatal factors affecting brain development.

Research indicates that MIA may disrupt immune signaling molecules, particularly cytokines, in the maternal-fetal environment [66-68]. These disruptions can cascade, affecting neural circuitry and synaptic connectivity, with heightened impact during critical periods marked by rapid developmental processes. The first trimester involves neural tube formation and early neuronal differentiation. In contrast, the second trimester is marked by extensive synaptogenesis and neuronal migration, rendering the developing brain particularly vulnerable to perturbations [69-71].

Understanding the nuanced interplay between MIA and fetal neurodevelopment within critical periods provides a framework for exploring disruptions in the finely tuned processes shaping the fetal brain. This knowledge may contribute to targeted interventions or preventative strategies to mitigate potential adverse effects on fetal neurodevelopment, offering insights into preventing or ameliorating neurodevelopmental disorders [72].

Beyond the prenatal period, longitudinal studies demonstrate that the consequences of MIA extend across the lifespan, impacting neurodevelopment and behavior. Childhood manifestations include cognitive deficits and emotional dysregulation, influencing academic and social domains. Increased susceptibility to psychiatric disorders, such as ASD and attention-deficit/hyperactivity disorder, has been consistently observed [73] .

As individuals transition into adolescence, the impact of MIA persists, influencing cognitive challenges, social difficulties, impulsivity, and a heightened risk of substance abuse. Long-term studies reveal a continued susceptibility to psychiatric disorders in adulthood, emphasizing the need for targeted interventions tailored to the unique needs of this population.

Incorporating this knowledge into public health strategies is crucial, emphasizing early identification and intervention during critical developmental periods to mitigate adverse outcomes associated with MIA. Mental health support and resources should be targeted to individuals exposed to MIA, addressing their specific needs across the lifespan.

MIA, a significant factor influencing neurodevelopment and contributing to ASD risk, exhibits variability based on timing and duration. Critical periods during gestation render the fetal brain more susceptible, with early exposure leading to distinct consequences. Temporal dynamics and prolonged immune activation further contribute to the complexity of MIA effects.

Investigating the molecular and cellular mechanisms underlying these long-term effects is imperative for developing targeted interventions and therapeutic strategies. Recognizing individual variability in response to MIA, influenced by genetic predispositions, environmental factors, and maternal health, enhances understanding precision and offers avenues for personalized therapeutic approaches.

Exploring the interplay between critical periods, temporal dynamics, and the duration of immune response provides a comprehensive framework for

future research. This framework offers insights that can inform targeted interventions, contributing to improved outcomes for individuals at risk of ASD due to MIA.

8. Potential Therapeutic Interventions

Efforts to uncover effective therapeutic strategies in the context of MIA and its potential association with ASD are gaining momentum. Researchers are delving into immunomodulatory strategies during pregnancy, seeking both existing methods and innovative interventions. The aim is to precisely mitigate the potential adverse effects of immune activation on fetal neurodevelopment [74].

A detailed exploration is unfolding within immunomodulatory strategies, focusing particularly on anti-inflammatory medications and dietary interventions. The evaluation goes beyond potential efficacy to unravel the underlying mechanisms by which these strategies influence the dynamic interplay between the maternal immune system and the developing fetal brain.

Recognizing the critical importance of early interventions, researchers are untangling the complexities of identifying infants at heightened risk due to maternal immune activation. This exploration opens doors to targeted and tailored interventions, spanning therapeutic measures and behavioral strategies designed to optimize neurodevelopment in infants facing challenges associated with MIA.

A transformative dimension emerges with the rise of precision medicine in MIA and ASD. This approach envisions a future where therapeutic interventions are tailored to individual patients' unique genetic, epigenetic, and environmental profiles. For at-risk infants, precision medicine holds promise in optimizing neurodevelopment by addressing the specific intricacies of each case [75].

Acknowledging population heterogeneity, ongoing genomic studies cover both maternal and fetal DNA. These studies aim to pinpoint key genetic markers associated with increased risk or protective factors against the neurodevelopmental impacts of MIA, offering crucial insights into the genetic underpinnings of susceptibility or resilience.

An in-depth exploration of epigenetic modifications becomes a cornerstone in deciphering the complexity of MIA-associated neurodevelopmental impacts. Researchers scrutinize changes in DNA methylation, histone modifications, and non-coding RNA expression to understand the dynamic interplay between environmental influences and gene expression, offering a nuanced perspective on potential therapeutic targets [76].

Precision medicine illuminates molecular intricacies and lays the groundwork for targeted interventions. Researchers explore how specific environmental factors induce epigenetic changes, aiming to develop interventions that precisely target and modify these epigenetic signatures. This approach holds promise for preventing or reversing adverse neurodevelopmental consequences associated with MIA, marking a significant advancement in therapeutic precision.

Environmental factors, such as maternal lifestyle, nutrition, and exposure to stressors, form integral components of precision medicine [77]. Researchers navigate this intricate landscape to explore how personalized interventions tailored to specific environmental contexts may optimize neurodevelopment in at-risk infants, extending beyond immediate prenatal considerations to include postnatal factors that profoundly shape developmental trajectories.

As precision medicine evolves beyond generalized interventions, the integration of genetic, epigenetic, and environmental data empowers clinicians and researchers to design targeted interventions aligned with each individual's unique biological and environmental characteristics [78]. This comprehensive approach enhances the potential for developing effective therapeutic solutions that address the specific needs of individuals exposed to MIA.

The therapeutic landscape expands beyond traditional pharmacological interventions, with behavioral strategies gaining prominence. This encompasses interventions across cognitive, sensory, and social domains, offering a holistic approach to address MIA-related challenges. Additionally, cutting-edge technologies, such as neuroimaging and biomarker discovery, are seamlessly integrated into therapeutic approaches, providing unprecedented insights into the neural correlates of MIA and enhancing precision and efficacy in pursuing therapeutic solutions.

Taken together, the ongoing evolution of potential therapeutic interventions in the context of MIA and ASD demands a comprehensive exploration of established and innovative, personalized approaches. This entails incorporating molecular insights, precision medicine principles, and emerging technologies to pave the way for transformative interventions in molecular neurobiology.

Conclusion

This review has delved into the intricate relationship between MIA and ASD. Key findings from epidemiological studies, insights into immunological mechanisms, and considerations of genetic and environmental interactions have significantly contributed to understanding ASD etiology.

The implications of this review are substantial, offering insights into preventive strategies. Recognizing the potential impact of MIA on fetal neurodevelopment opens avenues for targeted interventions during critical periods. Techniques such as immunomodulation during pregnancy and early interventions for at-risk infants emerge as promising approaches to reduce the likelihood and severity of ASD in susceptible populations.

Emphasizing the complexity of the MIA-ASD relationship, this review acknowledges the multifactorial nature of the disorder. The interplay of genetic susceptibility, environmental factors, and timing during critical periods underscores the need for a holistic approach to research and intervention. Ethical considerations and inherent challenges in this field warrant ongoing dialogue and scrutiny.

Despite notable progress, certain gaps persist in understanding the precise mechanisms connecting MIA to ASD, individual susceptibility variations, and the enduring consequences of immune activation. Future research should prioritize elucidating these mechanisms, exploring genetic and environmental modifiers, and unraveling intricate relationships between MIA and ASD.

To advance understanding, upcoming research should adopt interdisciplinary approaches integrating genetics, immunology, and neurobiology. Large-scale longitudinal inquiries using advanced imaging techniques and molecular methodologies promise a nuanced comprehension of temporal dynamics and the interplay of genetic and environmental factors. Technological strides, including single-cell sequencing, epigenomic profiling, and sophisticated neuroimaging, offer opportunities to gain deeper insights into the molecular and cellular changes associated with MIA and ASD.

While significant strides have been made in unraveling the intricacies of MIA and its potential role in ASD, more exploration is needed. Future research endeavors, guided by identified knowledge gaps and recommendations, hold promise for advancing the understanding of ASD and, ultimately, improving the lives of individuals and families affected by this complex neurodevelopmental disorder.

References

1. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
2. Karimi P, Kamali E, Mousavi SM, Karahmadi M. Environmental factors influencing the risk of autism. J Res Med Sci. 2017 Feb 16;22:27. doi: 10.4103/1735-1995.200272.
3. Thabault, M.; Turpin, V.; Maisterrena, A.; Jaber, M.; Egloff, M.; Galvan, L. Cerebellar and Striatal Implications in Autism Spectrum Disorders: From Clinical Observations to Animal Models. Int. J. Mol. Sci. 2022, 23, 2294. https://doi.org/10.3390/ijms23042294
4. Damiano CR, Mazefsky CA, White SW, Dichter GS. Future directions for research in autism spectrum disorders. J Clin Child Adolesc Psychol. 2014;43(5):828-43. doi: 10.1080/15374416.2014.945214
5. Han, V. X., Patel, S., Jones, H. F. & Dale, R. C. Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. Nat. Rev. Neurol.2021. 17, 564–579
6. Ellul, P., Maruani, A., Vantalon, V. Humeau E, Amestoy A, Anchordoqui A, et al. Maternal immune activation during pregnancy is associated with more difficulties in socio-adaptive behaviors in autism spectrum disorder. Sci Rep 13, 17687 (2023). https://doi.org/10.1038/s41598-023-45060-z.
7. Zawadzka A, Cieślik M, Adamczyk A. The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the

Evidence, Proposed Mechanisms and Implications for Treatment. Int J Mol Sci. 2021 Oct 26;22(21):11516. doi: 10.3390/ijms222111516

8. Sotgiu S, Manca S, Gagliano A, Minutolo A, Melis MC, Pisuttu G, Scoppola C, Bolognesi E, Clerici M, Guerini FR, Carta A. Immune regulation of neurodevelopment at the mother-foetus interface: the case of autism. Clin Transl Immunology. 2020 Nov 13;9(11):e1211. doi: 10.1002/cti2.1211
9. Girault JB, Piven J. The Neurodevelopment of Autism from Infancy Through Toddlerhood. Neuroimaging Clin N Am. 2020 Feb;30(1):97-114. doi: 10.1016/j.nic.2019.09.009.
10. Weir E., Allison C., Baron-Cohen S. Autistic adults have poorer quality healthcare and worse health based on self-report data. Mol. Autism. 2022;13:23. doi: 10.1186/s13229-022-00501-
11. Pan YH, Wu N, Yuan XB. Toward a Better Understanding of Neuronal Migration Deficits in Autism Spectrum Disorders. Front Cell Dev Biol. 2019 Sep 20;7:205. doi: 10.3389/fcell.2019.00205.
12. Wolff JJ, Jacob S, Elison JT. The journey to autism: Insights from neuroimaging studies of infants and toddlers. Dev Psychopathol. 2018 May;30(2):479-495. doi: 10.1017/S0954579417000980.
13. Yang G, Shcheglovitov A. Probing disrupted neurodevelopment in autism using human stem cell-derived neurons and organoids: An outlook into future diagnostics and drug development. Dev Dyn. 2020 Jan;249(1):6-33. doi: 10.1002/dvdy.100.
14. Marotta R, Risoleo MC, Messina G, Parisi L, Carotenuto M, Vetri L, Roccella M. The Neurochemistry of Autism. Brain Sci. 2020 Mar 13;10(3):163. doi: 10.3390/brainsci10030163.
15. Hernandez LM, Rudie JD, Green SA, Bookheimer S, Dapretto M. Neural signatures of autism spectrum disorders: insights into brain network dynamics. Neuropsychopharmacology. 2015 Jan;40(1):171-89. doi: 10.1038/npp.2014.172. Epub 2014 Jul 11. PMID: 25011468; PMCID: PMC4262896.
16. Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. Science. 2016 Aug 19;353(6301):772-7. doi: 10.1126/science.aag3194.
17. Dutta S., Sengupta P. Defining pregnancy phases with cytokine shift. J. Pregnancy Reprod. 2017;1:1–3. doi: 10.15761/JPR.1000124.
18. Yang F., Zheng Q., Jin L. Dynamic Function and Composition Changes of Immune Cells During Normal and Pathological Pregnancy at the Maternal-Fetal Interface. Front. Immunol. 2019;10:2317. doi: 10.3389/fimmu.2019.02317.
19. Ochoa-Bernal M.A., Fazleabas A.T. Physiologic Events of Embryo Implantation and Decidualization in Human and Non-Human Primates. Int. J. Mol. Sci. 2020;21:1973. doi: 10.3390/ijms21061973.
20. Yockey L.J., Iwasaki A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. Immunity. 2018;49:397–412. doi: 10.1016/j.immuni.2018.07.017.
21. Equils O., Kellogg C., McGregor J., Gravett M., Neal-Perry G., Gabay C. The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications. Biol. Reprod. 2020;103:684–694. doi: 10.1093/biolre/ioaa102.
22. Zhao B., Schwartz J.P. Involvement of cytokines in normal CNS development and neurological diseases: Recent progress and perspectives. J. Neurosci. Res. 1998;52:7–16.
23. Parker-Athill E.C., Tan J. Maternal immune activation and autism spectrum disorder: Interleukin-6 signaling as a key mechanistic pathway. Neuro-Signals. 2010;18:113–128. doi: 10.1159/000319828.
24. Phillips NLH, Roth TL. Animal Models and Their Contribution to Our Understanding of the Relationship Between Environments, Epigenetic Modifications, and Behavior. Genes (Basel). 2019 Jan 15;10(1):47. doi: 10.3390/genes10010047. PMID: 30650619; PMCID: PMC6357183.
25. Hussain T, Murtaza G, Kalhoro DH, Kalhoro MS, Yin Y, Chughtai MI, Tan B, Yaseen A, Rehman ZU. Understanding the Immune System in Fetal Protection and Maternal Infections during Pregnancy. J Immunol Res. 2022 Jun 24;2022:7567708. doi: 10.1155/2022/7567708.
26. Huang N, Chi H, Qiao J. Role of Regulatory T Cells in Regulating Fetal-Maternal Immune Tolerance in Healthy Pregnancies and Reproductive Diseases. Front Immunol. 2020 Jun 26;11:1023. doi: 10.3389/fimmu.2020.01023.
27. Woods RM, Lorusso JM, Fletcher J, ElTaher H, McEwan F, Harris I, Kowash HM, D'Souza SW, Harte M, Hager R, Glazier JD. Maternal immune

activation and role of placenta in the prenatal programming of neurodevelopmental disorders. Neuronal Signal. 2023 May 31;7(2):NS20220064. doi: 10.1042/NS20220064.
28. Oyesola OO, Souza COS, Loke P. The Influence of Genetic and Environmental Factors and Their Interactions on Immune Response to Helminth Infections. Front Immunol. 2022 Apr 29;13:869163. doi: 10.3389/fimmu.2022.869163.
29. Lu-Culligan A, Iwasaki A. The Role of Immune Factors in Shaping Fetal Neurodevelopment. Annu Rev Cell Dev Biol. 2020 Oct 6;36:441-468. doi: 10.1146/annurev-cellbio-021120-033518.
30. Li Z, Zhu YX, Gu LJ, Cheng Y. Understanding autism spectrum disorders with animal models: applications, insights, and perspectives. Zool Res. 2021 Nov 18;42(6):800-824. doi: 10.24272/j.issn.2095-8137.2021.251.
31. Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, et al Maternal antibrain antibodies in autism. Brain, Behavior, and Immunity. 2007;21(3):351–357. doi: 10.1016/j.bbi.2006.08.005
32. Haddad FL, Patel SV, Schmid S Maternal immune activation by Poly I: C as a preclinical model for neurodevelopmental disorders: a focus on autism and schizophrenia. Neuroscience & Biobehavioral Reviews. 2020;113:546–567
33. Elsworth JD, Jentsch JD, VandeVoort CA, Roth RH, Redmond DE Jr, Leranth C Prenatal exposure to bisphenol A impacts midbrain dopamine neurons and hippocampal spine synapses in non-human primates. NeuroToxicology. 2013;35:113–120. doi: 10.1016/j.neuro.2013.01.001
34. Jiang HY, Xu LL, Shao L, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: A systematic review and meta-analysis. Brain Behav Immun. 2016;58:165-172. doi:10.1016/j.bbi.2016.06.005
35. Shuid, A.N.; Jayusman, P.A.; Shuid, N.; Ismail, J.; Kamal Nor, N.; Mohamed, I.N. Association between Viral Infections and Risk of Autistic Disorder: An Overview. Int. J. Environ. Res. Public Health 2021, 18, 2817. https://doi.org/10.3390/ijerph18062817
36. Zerbo O, Qian Y, Yoshida C, Grether JK, Van de Water J, Croen LA. Maternal Infection During Pregnancy and Autism Spectrum Disorders. J Autism Dev Disord. 2015 Dec;45(12):4015-25. doi: 10.1007/s10803-013-2016-3. PMID: 24366406; PMCID: PMC4108569.
37. Kaminski VL, Michita RT, Ellwanger JH, Veit TD, Schuch JB, Riesgo RDS, Roman T, Chies JAB. Exploring potential impacts of pregnancy-related maternal immune activation and extracellular vesicles on immune alterations observed in autism spectrum disorder. Heliyon. 2023 Apr 29;9(5):e15593. doi: 10.1016/j.heliyon.2023.e15593..
38. Hall MB, Willis DE, Rodriguez EL, Schwarz JM. Maternal immune activation as an epidemiological risk factor for neurodevelopmental disorders: Considerations of timing, severity, individual differences, and sex in human and rodent studies. Front Neurosci. 2023 Apr 13;17:1135559. doi: 10.3389/fnins.2023.1135559. PMID: 37123361; PMCID: PMC10133487.
39. Brown AS and Derkits EJ.Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010 167, 261–280. 10.1176/appi.ajp.2009.09030361
40. Zerbo O. et al. Month of conception and risk of autism. Epidemiology 2011 22, 469–47.1097/EDE.0b013e31821d0b53
41. Lee BK et al. Maternal hospitalization with infection during pregnancy and risk of autismspectrum disorders. Brain Behav Immun 2015 44, 100–105. 10.1016/j.bbi.2014.09.001
42. Robinson-Agramonte MLA, Noris García E, Fraga Guerra J, Vega Hurtado Y, Antonucci N, Semprún-Hernández N, Schultz S, Siniscalco D. Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It? Int J Mol Sci. 2022 Mar 11;23(6):3033. doi: 10.3390/ijms23063033. PMID: 35328471; PMCID: PMC8955336.
43. Lipkin WI, Bresnahan M, Susser E. Cohort-guided insights into gene-environment interactions in autism spectrum disorders. Nat Rev Neurol. 2023 Feb;19(2):118-125. doi: 10.1038/s41582-022-00764-0. Epub 2023 Jan 16. PMID: 36646930; PMCID: PMC9841497.
44. Patel S, Dale RC, Rose D, Heath B, Nordahl CW, Rogers S, Guastella AJ, Ashwood P. Maternal immune conditions are increased in males with autism spectrum disorders and are associated with behavioural and emotional but not cognitive co-morbidity. Transl Psychiatry. 2020 Aug 14;10(1):286. doi: 10.1038/s41398-020-00976-2.
45. Chaste P, Leboyer M. Autism risk factors: genes, environment, and gene-environment interactions.

Dialogues Clin Neurosci. 2012 Sep;14(3):281-92. doi: 10.31887/DCNS.2012.14.3/pchaste

46. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal Immunological Adaptation During Normal Pregnancy. Front Immunol. 2020 Oct 7;11:575197. doi: 10.3389/fimmu.2020.575197.
47. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011 Mar;1221(1):80-7. doi: 10.1111/j.1749-6632.2010.05938.x.
48. Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. Science. 2016 Aug 19;353(6301):772-7. doi: 10.1126/science.aag3194. PMID: 27540164; PMCID: PMC5650490.
49. Knuesel I, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nature reviews Neurology. 2014;10:643–660. [PubMed] [Google Scholar]
50. Reisinger S, et al. The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther. 2015;149:213–226. [PubMed] [Google Scholar]
51. Selten JP, Frissen A, Lensvelt-Mulders G, Morgan VA. Schizophrenia and 1957 pandemic of influenza: meta-analysis. Schizophr Bull. 2010;36:219–228. [PMC free article] [PubMed] [Google Scholar]
52. Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nature reviews Neuroscience. 2015;16:469–486. [PMC free article] [PubMed] [Google Scholar]
53. Blomstrom A, et al. Associations Between Maternal Infection During Pregnancy, Childhood Infections, and the Risk of Subsequent Psychotic Disorder--A Swedish Cohort Study of Nearly 2 Million Individuals. Schizophr Bull. 2016; 42:125–133.
54. Zawadzka A, Cieślik M, Adamczyk A. The role of maternal immune activation in the pathogenesis of autism: a review of the evidence, proposed mechanisms and implications for treatment. Int J Mol Sci. (2021) 22:1516. 10.3390/ijms222111516
55. Saghazadeh A, Ataeinia B, Keynejad K, Abdolalizadeh A, Hirbod-Mobarakeh A, Rezaei N, et al.. meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude. J Psychiatr Res. (2019) 115:90–102. 10.1016/j.jpsychires.2019.05.019
56. Koo JW, Wohleb ES. How stress shapes neuroimmune function: implications for the neurobiology of psychiatric disorders. Biol Psychiatry. (2021) 90:74–84. 10.1016/j.biopsych.2020.11.007
57. Heuer LS, Croen LA, Jones KL, Yoshida CK, Hansen RL, Yolken R, et al.. An Exploratory Examination of neonatal cytokines and chemokines as predictors of autism risk: the early markers for autism study. Biol Psychiatry. (2019) 86:255–64. 10.1016/j.biopsych.2019.04.037
58. Zhang, W., Xiao, D., Mao, Q. et al. Role of neuroinflammation in neurodegeneration development. Sig Transduct Target Ther 8, 267 (2023). https://doi.org/10.1038/s41392-023-01486-5
59. Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, Bronsard G, Bonnot O, Weismann-Arcache C, Botbol M, Lauth B, Ginchat V, Roubertoux P, Barburoth M, Kovess V, Geoffray MM, Xavier J. Gene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front Psychiatry. 2014 Aug 4;5:53. doi: 10.3389/fpsyt.2014.00053
60. Rylaarsdam L, Guemez-Gamboa A. Genetic Causes and Modifiers of Autism Spectrum Disorder. Front Cell Neurosci. 2019 Aug 20;13:385. doi: 10.3389/fncel.2019.00385.
61. Cheroni, C., Caporale, N. & Testa, G. Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences, and interactions in ASD developmental pathophysiology. Molecular Autism 11, 69 (2020). https://doi.org/10.1186/s13229-020-00370-1
62. Strathearn L, Momany A, Kovács EH, Guiler W, Ladd-Acosta C. The intersection of genome, epigenome and social experience in autism spectrum disorder: Exploring modifiable pathways for intervention. Neurobiol Learn Mem. 2023;202:107761. doi:10.1016/j.nlm.2023.107761
63. Siniscalco D, Cirillo A, Bradstreet JJ, Antonucci N. Epigenetic findings in autism: new perspectives for therapy. Int J Environ Res Public Health. 2013 Sep 11;10(9):4261-73. doi: 10.3390/ijerph10094261.
64. Bergdolt L, Dunaevsky A. Brain changes in a maternal immune activation model of neurodevelopmental brain disorders. Prog

Neurobiol. 2019 Apr;175:1-19. doi: 10.1016/j.pneurobio.2018.12.002.
65. Conway F, Brown AS. Maternal Immune Activation and Related Factors in the Risk of Offspring Psychiatric Disorders. Front Psychiatry. 2019 Jun 28;10:430. doi: 10.3389/fpsyt.2019.00430.
66. Mattei D., Schweibold R. and Wolf S.A. Brain in flames - animal models of psychosis: utility and limitations. Neuropsychiatr. Dis. Treat. 2015 11, 1313–1329 10.2147/NDT.S65564
67. Meyer U., Feldon J. and Yee B.K. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr. Bull. 2009 35, 959–972 10.1093/schbul/sbn022]
68. Rapoport J.C., Addington A.M. and Frangou S. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry2005 10, 434–449 10.1038/sj.mp.4001642
69. Ming, G.; Song, H. Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions. Neuron 2011, 70, 687–702
70. Marzola, P.; Melzer, T.; Pavesi, E.; Gil-Mohapel, J.; Brocardo, P.S. Exploring the Role of Neuroplasticity in Development, Aging, and Neurodegeneration. Brain Sci. 2023, 13, 1610. https://doi.org/10.3390/brainsci13121610
71. Leibovitz Z, Lerman-Sagie T, Haddad L. Fetal Brain Development: Regulating Processes and Related Malformations. Life (Basel). 2022 May 29;12(6):809. doi: 10.3390/life12060809.
72. Gundacker A, Cuenca Rico L, Stoehrmann P, Tillmann KE, Weber-Stadlbauer U, Pollak DD. Interaction of the pre- and postnatal environment in the maternal immune activation model. Discov Ment Health. 2023;3(1):15. doi: 10.1007/s44192-023-00042-5.
73. Paulus FW, Ohmann S, Möhler E, Plener P, Popow C. Emotional Dysregulation in Children and Adolescents With Psychiatric Disorders. A Narrative Review. Front Psychiatry. 2021 Oct 25;12:628252. doi: 10.3389/fpsyt.2021.628252.
74. Bucknor MC, Gururajan A, Dale RC, Hofer MJ. A comprehensive approach to modeling maternal immune activation in rodents. Front Neurosci. 2022 Dec 16;16:1071976. doi: 10.3389/fnins.2022.1071976. PMID: 36590294; PMCID: PMC9800799.
75. Beversdorf DQ, Anagnostou E, Hardan A, Wang P, Erickson CA, Frazier TW, Veenstra-VanderWeele J. Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Front Psychiatry. 2023 Jan 19;13:1079006. doi: 10.3389/fpsyt.2022.1079006.
76. Grezenko H, Ekhator C, Nwabugwu NU, Ganga H, Affaf M, Abdelaziz AM, Rehman A, Shehryar A, Abbasi FA, Bellegarde SB, Khaliq AS. Epigenetics in Neurological and Psychiatric Disorders: A Comprehensive Review of Current Understanding and Future Perspectives. Cureus. 2023 Aug 23;15(8):e43960. doi: 10.7759/cureus.43960.
77. Subramanian M, Wojtusciszyn A, Favre L, Boughorbel S, Shan J, Letaief KB, Pitteloud N, Chouchane L. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J Transl Med. 2020 Dec 9;18(1):472. doi: 10.1186/s12967-020-02658-5.
78. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021 Jan;14(1):86-93. doi: 10.1111/cts.12884.